Which drugs may be hit with negotiations if the reconciliation bill passes? Wall St. analysts explain
Beyond the back and forth of whether Democrats’ drug price negotiation plan is necessary to bring down costs, or just a thinly veiled attempt at price controls, the nuts and bolts of the deal mean pharma companies will inevitably see the tail ends of certain small molecule and biologic sales peter out before they otherwise would have in today’s marketplace.
While the bill’s text is not set in stone, and the Senate parliamentarian may still take issue with the excise tax that CMS will use to ensure companies comply with the negotiated prices, SVB Securities explained to investors how more than a dozen drugs from Eli Lilly, AstraZeneca, AbbVie and J&J, among others, would lose out on some revenue just before their generic competitors hit the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.